

Jacqueline A Shaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9205428/publications.pdf>

Version: 2024-02-01

101
papers

10,286
citations

76326

40
h-index

39675

94
g-index

106
all docs

106
docs citations

106
times ranked

16702
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-free DNA analysis in current cancer clinical trials: a review. <i>British Journal of Cancer</i> , 2022, 126, 391-400.	6.4	74
2	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. <i>NAR Cancer</i> , 2022, 4, .	3.1	4
3	A local human V α 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	13.2	39
4	Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nature Communications</i> , 2021, 12, 1751.	12.8	66
5	Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. <i>Annals of Oncology</i> , 2021, 32, 681-684.	1.2	6
6	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 465-476.	2.5	1
7	Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. <i>Annals of Oncology</i> , 2021, 32, 1057-1060.	1.2	4
8	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
9	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF- κ B. <i>Oncogene</i> , 2021, 40, 1077-1090.	5.9	18
10	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. <i>JCO Precision Oncology</i> , 2021, 5, 1768-1776.	3.0	12
11	Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1271-1279.	6.4	27
12	Detection of Breast Cancer ESR1 p.E380Q Mutation on an ISFET Lab-on-Chip Platform. , 2020, , .		9
13	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	6.4	51
14	Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. <i>European Journal of Preventive Cardiology</i> , 2020, 28, e28-e31.	1.8	12
15	A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. <i>Scientific Reports</i> , 2020, 10, 4553.	3.3	35
16	The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4483.	4.1	8
17	Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2020, 122, 1077-1084.	6.4	13
18	The liquid biopsy: towards standardisation in preparation for prime time. <i>Lancet Oncology</i> , The, 2019, 20, 758-760.	10.7	23

#	ARTICLE	IF	CITATIONS
19	Opportunities and challenges of circulating biomarkers in neuroblastoma. <i>Open Biology</i> , 2019, 9, 190056.	3.6	22
20	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019, 25, 4255-4263.	7.0	281
21	Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	16
22	Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 149.	5.0	89
23	A framework for the development of effective anti-metastatic agents. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 185-204.	27.6	223
24	A response to the Chief Medical Officer's report on Genomic Medicine: a catalyst for transformation. <i>Personalized Medicine</i> , 2018, 15, 5-8.	1.5	2
25	Use of the liquid biopsy for monitoring patients with cancer. <i>Pathology</i> , 2018, 50, S32.	0.6	0
26	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	16.8	448
27	Liquid biopsies: An introduction to circulating tumour cells and ctDNA. <i>Pathology</i> , 2018, 50, S30.	0.6	0
28	Circulating tumour-derived DNA in metastatic soft tissue sarcoma. <i>Oncotarget</i> , 2018, 9, 10549-10560.	1.8	29
29	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. <i>Cell Death and Disease</i> , 2018, 9, 894.	6.3	34
30	Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. <i>Heliyon</i> , 2018, 4, e00699.	3.2	92
31	Integrating next generation sequencing into the clinic. <i>Pathology</i> , 2018, 50, S30-S31.	0.6	0
32	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. <i>Clinical Cancer Research</i> , 2017, 23, 88-96.	7.0	186
33	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 532-541.	3.2	81
34	Telomere maintenance in soft tissue sarcomas. <i>Journal of Clinical Pathology</i> , 2017, 70, 371-377.	2.0	1
35	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	14.3	323
36	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287

#	ARTICLE	IF	CITATIONS
37	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
38	The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 459-470.	3.1	11
39	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	28.9	968
40	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. <i>BMC Cancer</i> , 2017, 17, 697.	2.6	94
41	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 87221-87233.	1.8	38
42	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 751-755.	3.1	21
43	A preliminary study to compare cfDNA levels in lung cancer cases and high risk controls to evaluate the role of cfDNA levels in early lung cancer detection. <i>European Journal of Surgical Oncology</i> , 2016, 42, S243-S244.	1.0	1
44	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 479-491.	7.0	14
45	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 974-982.	3.2	155
46	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. <i>Oncogene</i> , 2015, 34, 2103-2114.	5.9	17
47	The pioneer factor PBX1 is a novel driver of metastatic progression in ER \pm -positive breast cancer. <i>Oncotarget</i> , 2015, 6, 21878-21891.	1.8	45
48	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906.	5.6	185
49	Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph Nodes. <i>PLoS ONE</i> , 2014, 9, e115346.	2.5	15
50	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 581-590.	2.5	76
51	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 295-309.	2.5	21
52	The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy. <i>Future Oncology</i> , 2014, 10, 2555-2560.	2.4	2
53	Circulating free DNA in the management of breast cancer. <i>Annals of Translational Medicine</i> , 2014, 2, 3.	1.7	23
54	Genomic instability in pre-neoplastic colonic lesions. <i>Oncogene</i> , 2013, 32, 5331-5332.	5.9	0

#	ARTICLE	IF	CITATIONS
55	Hide and seek: tell-tale signs of breast cancer lurking in the blood. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 289-302.	5.9	18
56	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). <i>Annals of Oncology</i> , 2013, 24, 924-930.	1.2	13
57	LMTK3 is implicated in endocrine resistance via multiple signaling pathways. <i>Oncogene</i> , 2013, 32, 3371-3380.	5.9	40
58	Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids. <i>PLoS ONE</i> , 2013, 8, e77963.	2.5	159
59	Determination of Breast Cancer Dormancy: Analysis of Circulating Free DNA Using SNP 6.0 Arrays. , 2013, , 35-50.		0
60	The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. <i>British Journal of Cancer</i> , 2012, 106, 375-382.	6.4	16
61	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. <i>Nucleic Acids Research</i> , 2012, 40, e82-e82.	14.5	356
62	Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. <i>Genome Research</i> , 2012, 22, 220-231.	5.5	165
63	Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. <i>Biomarkers in Medicine</i> , 2011, 5, 87-91.	1.4	31
64	Detection of HER2 amplification in circulating free DNA in patients with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1342-1348.	6.4	74
65	Expression of tenascin-C and its isoforms in the breast. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 595-606.	5.9	37
66	Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. <i>Breast Cancer Research</i> , 2010, 12, R57.	5.0	28
67	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. <i>Breast Cancer Research</i> , 2009, 11, R24.	5.0	101
68	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 98-107.	3.8	90
69	Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission <i>in vivo</i> . <i>Cancer Research</i> , 2008, 68, 7760-7768.	0.9	64
70	Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression. <i>Clinical Cancer Research</i> , 2007, 13, 6673-6680.	7.0	55
71	Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. <i>Breast Cancer Research</i> , 2007, 9, R67.	5.0	42
72	The Importance of Careful Blood Processing in Isolation of Cell-Free DNA. <i>Annals of the New York Academy of Sciences</i> , 2006, 1075, 313-317.	3.8	66

#	ARTICLE	IF	CITATIONS
73	Î±-Tocopherol supplementation does not affect monocyte endothelial adhesion or C-reactive protein levels but reduces soluble vascular adhesion molecule-1 in the plasma of healthy subjects. Redox Report, 2006, 11, 214-222.	4.5	6
74	Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. Oncogene, 2004, 23, 3434-3443.	5.9	20
75	Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. Journal of Pathology, 2003, 201, 562-572.	4.5	195
76	Vitamin C supplementation in normal subjects reduces constitutive ICAM-1 expression. Biochemical and Biophysical Research Communications, 2003, 308, 339-345.	2.1	44
77	Effects of oral vitamin C on monocyte: endothelial cell adhesion in healthy subjects. Biochemical and Biophysical Research Communications, 2002, 294, 1161-1168.	2.1	33
78	Sporadic breast cancer in young women: Prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. International Journal of Cancer, 2002, 98, 205-209.	5.1	38
79	Evidence that superficial basal cell carcinoma is monoclonal from analysis of the Ptch1 gene locus. British Journal of Dermatology, 2002, 147, 931-935.	1.5	17
80	Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. British Journal of Surgery, 2002, 87, 1569-1575.	0.3	66
81	Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. Journal of Pathology, 2002, 198, 450-457.	4.5	89
82	Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Journal of Clinical Pathology, 2001, 54, 300-306.	1.9	41
83	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 2001, 20, 1509-1518.	5.9	341
84	Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno-electron microscopic study. Journal of Pathology, 2000, 191, 61-66.	4.5	9
85	Expression of oestrogen receptor alpha variants in non-malignant breast and early invasive breast carcinomas. Journal of Pathology, 2000, 192, 159-165.	4.5	13
86	Microsatellite alterations plasma DNA of primary breast cancer patients. Clinical Cancer Research, 2000, 6, 1119-24.	7.0	64
87	Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrology Dialysis Transplantation, 1999, 14, 1234-1237.	0.7	115
88	Microsatellite instability in ductal carcinoma in situ of the breast. , 1998, 185, 18-24.		29
89	Reproducibility in the Quantification of mRNA Levels by RT-PCR-ELISA and RT Competitive-PCR-ELISA. BioTechniques, 1998, 24, 652-658.	1.8	69
90	Numerical chromosomal aberrations in Hodgkin's disease detected by in situ hybridisation on routine paraffin sections.. Journal of Clinical Pathology, 1997, 50, 553-558.	2.0	5

#	ARTICLE	IF	CITATIONS
91	Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. British Journal of Cancer, 1997, 75, 1324-1329.	6.4	65
92	Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. British Journal of Cancer, 1997, 76, 1558-1561.	6.4	63
93	Molecular pathology of breast cancer and its application to clinical management. Cancer and Metastasis Reviews, 1997, 16, 5-27.	5.9	53
94	AMPLIFICATION OF SPECIFIC mRNA FROM A SINGLE HUMAN RENAL GLOMERULUS, WITH AN APPROACH TO THE SEPARATION OF EPITHELIAL CELL mRNA. , 1996, 180, 188-193.		23
95	Microsatellite instability in early sporadic breast cancer. British Journal of Cancer, 1996, 73, 1393-1397.	6.4	65
96	AMPLIFICATION OF SPECIFIC mRNA FROM A SINGLE HUMAN RENAL GLOMERULUS, WITH AN APPROACH TO THE SEPARATION OF EPITHELIAL CELL mRNA. Journal of Pathology, 1996, 180, 188-193.	4.5	2
97	Identification of CpG islands in a physical map encompassing the Friedreich's ataxia locus. Genomics, 1991, 9, 90-95.	2.9	27
98	Acadian and classical forms of Friedreich ataxia are most probably caused by mutations at the same locus. American Journal of Medical Genetics Part A, 1989, 33, 266-268.	2.4	35
99	Mapping of mutation causing Friedreich's ataxia to human chromosome 9. Nature, 1988, 334, 248-250.	27.8	343
100	Exclusion of the Friedreich ataxia gene from chromosome 19. Human Genetics, 1987, 76, 186-190.	3.8	6
101	Peptide nucleic acid clamping to improve the sensitivity of Ion Torrent-based detection of an oncogenic mutation in KRAS. Matters, 0, , .	1.0	5